Lightpoint appoints Board of Directors

Lightpoint Medical, a privately-held medical device company developing advanced imaging technologies for intra-operative cancer detection, announced that the company has appointed four new members to its Board of Directors…

The following Directors were named to the company's Board:

William (Bill) Allan, MBA, is an internationally experienced medical device senior executive and entrepreneur who has held a number of general management and global leadership positions with large multinational medical device companies including Stryker, Smith & Nephew, Angiodynamics, and Orthovita and is currently CEO of Vascular Flow Technologies. In addition he has been instrumental in the successful transition of three small medical device companies to exit. He has a strong track record of building businesses, developing and launching new products and has worked in Europe, Africa and North America. Educated at the University of Edinburgh, University of Cape Town and INSEAD Business School, Bill is a mentor at Cambridge University (Judge) Business School, and a Non-Executive Director at Otivio AS, the Eastern Area Academic Health Sciences Network and has been a council member of ABHI (Association of British Healthcare Industries).

Elizabeth Usher, MBA, has more than 20 years of experience in the medical device industry successfully developing and executing commercial strategies for profitable growth. She is currently the Chief Marketing, Sales, and Communications Officer for the College of American Pathologists. Previously, she held executive leadership positions at GE Healthcare including Chief Marketing Officer for Surgery, VP General Manager for Molecular Imaging, and VP General Manager International of Oncura. She also held multiple commercial roles at Amersham Health (today part of GE Healthcare), developing and expanding their therapy business internationally. She has an MBA in International Business from Thunderbird School of Global Management and a Bachelor of Science degree from Georgia Institute of Technology.

Martin Jamieson was most recently Group CEO of Rayner Surgical, a globally based ophthalmic company noted for developing and manufacturing the first intraocular lens. Previously, he was Managing Director of Smiths Medical International where he gained extensive experience in key international markets, company and distributor acquisitions and organizational development. Martin currently works with a number of private equity houses and is a Non-Executive Director of a large NHS Foundation Trust Hospital where he chairs the Audit Committee.

Ian Quirk is the Director of Clinical and Regulatory Affairs at Lightpoint Medical. He has more than 20 years of experience in the medical device industry, having led multiple successful market approvals in US and Europe. Before joining Lightpoint, he was the Worldwide Director of Clinical and Regulatory Affairs at Ranier Technology. Previously, he held clinical, regulatory and quality director roles at Cardiak and Lombard Medical. Ian holds an MSc in Evidence-Based Medicine from Oxford University and a BSc (Honours) in Chemistry from Kingston University.

"We're delighted to welcome such highly accomplished industry leaders to our Board of Directors," commented Dr David Tuch, CEO of Lightpoint Medical. "The new Directors' deep experience in international markets and commercial development will help guide Lightpoint through its next growth phase. We look forward to working with our new Board members to bring Lightpoint's transformative technology to surgery clinics worldwide."

About Lightpoint Medical

Lightpoint Medical is an innovative medical device company dedicated to improving health outcomes for cancer patients through image-guided surgery. The company's ground-breaking molecular imaging technology, based on Cerenkov Luminescence, has the potential to detect cancer in real-time during surgery and thereby reduce the need for repeat operations.

Lightpoint is currently over-subscribed on their funding round but they are still open to some external investment, if you would like to know more information about the round, email Simon Heywood at